Page 85 - FBL AR 2019-20

CORPORATE STATUTORY FINANCIAL
OVERVIEW STATEMENTS STATEMENTS

• Reconciliation of Share Capital Audit
Share Capital Audit for the total admitted capital with National Securities Depository Limited (NSDL) and Central Depository Services
(India) Limited (CDSL) and the total issued and listed capital of the Company has been done by a Practising Company Secretary on
a quarterly basis and the Reconciliation of Share Capital Audit Reports were issued thereon during the year under review. The audit
confirms that the total issued / paid – up capital is in agreement with the total number of shares in physical form and the total number
of dematerialised shares held with NSDL and CDSL..
• Compliance with Mandatory Requirements
The Company has complied with all the mandatory requirements, as applicable in terms of Schedule V of the Listing Regulations.
• Compliance with Discretionary Requirements as per Part E of Schedule II of the Listing Regulations
The Company has adopted D & E of the Non-Mandatory requirements as provided in Part E of Schedule II of the Listing Regulations and
not adopted A, B and C since they are discretionary requirements.
• Response of the Company’s management in relation to the –
(a) ‘Basis of qualified opinion’ and
(b) ‘Qualified opinion’
as mentioned in the Independent Auditor’s Report in page no. 106 of this Annual Report is:
The company had given to non-related party, advances in the nature of Inter Corporate Deposits and trade advances in various tranches over
the period of last twenty months for the development of the new product i. e. cholesterol from Fish Oil. The total amount outstanding as on
March 31, 2020 is H2,430.88 Lakhs, including interest of H198.88 Lakhs. The Company has started the export sales of the new product and is
confident that it shall be able to recover the trade advances and Inter corporate deposit amount alongwith interest in next 12 months period.

(i) Management’s estimation on the impact of audit qualification: Not Applicable;
(ii) If management is unable to estimate the impact, reasons for the same: The advance in the nature of ICD and trade advances were against
development of the new product i.e. cholesterol from Fish Oil. The sales of the product has also commenced. Hence the management
is unable to estimate the impact.

MEANS OF COMMUNICATION
The Quarterly, Half Yearly and Annual results, published in the proforma prescribed under the Listing Regulations, are approved by the Audit
Committee and taken on record by the Board of Directors of the Company within the prescribed time limit. The approved results are forthwith
sent to BSE Limited in prescribed format where the Company’s shares are listed.
Newspapers wherein quarterly results are published: Business Standard (English), Sakal (Marathi)
Any website, where displayed: Yes, BSE website (www.bseindia.com) and the Company’s website (www.
fermentabiotech.com)
Online filing with BSE Corporate Compliance & Listing All periodical compliances of the Company as per Listing Regulations are also
Centre: being filed online with the BSE Corporate Compliance & Listing Centre.
SEBI Complaints Redress System (SCORES) : All periodical compliances of the Company as per Listing Regulations are also
being filed online with the BSE Corporate Compliance & Listing Centre.
The investor complaints, if any, can be uploaded on the SCORES. These
complaints are processed in a centralized web-based complaints redress
system of SEBI (SCORES). The salient features of this system is centralised
database of all complaints, online upload of Action Taken Reports (ATRs) and
online viewing by investors of actions taken on the complaint and its current
status.
Whether it also displays official news releases and Yes
presentations made to institutional investors or to analysts:
Management discussion and analysis report (MD&A) is a Management discussion and analysis report (MD&A) is a part of the Annual
part of the Annual report or not: report or not:

83